You just read:

Chipscreen Biosciences Announces that a Pivotal Phase III Clinical Trial of Chidamide in Combination with Exemestane in Patients with Breast Cancer Reached Primary Endpoint

News provided by

Shenzhen Chipscreen Biosciences, Ltd.

May 29, 2018, 06:00 ET